SG10201809901SA - Generating Pluripotent Cells De Novo - Google Patents

Generating Pluripotent Cells De Novo

Info

Publication number
SG10201809901SA
SG10201809901SA SG10201809901SA SG10201809901SA SG10201809901SA SG 10201809901S A SG10201809901S A SG 10201809901SA SG 10201809901S A SG10201809901S A SG 10201809901SA SG 10201809901S A SG10201809901S A SG 10201809901SA SG 10201809901S A SG10201809901S A SG 10201809901SA
Authority
SG
Singapore
Prior art keywords
novo
pluripotent cells
generating pluripotent
generating
assays
Prior art date
Application number
SG10201809901SA
Inventor
Charles A Vacanti
Martin P Vacanti
Koji Kojima
Haruko Obokata
Teruhiko Wakayama
Yoshiki Sasai
Masayuki Yamato
Original Assignee
Vcell Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vcell Therapeutics Inc filed Critical Vcell Therapeutics Inc
Publication of SG10201809901SA publication Critical patent/SG10201809901SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2521/00—Culture process characterised by the use of hydrostatic pressure, flow or shear forces
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2523/00—Culture process characterised by temperature

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Abstract

GENERATING PLURIPOTENT CELLS DE NOVO The technology described herein relates to methods, assays, and compositions relating to causing a cell to assume a more pluripotent state, e.g. without introducing foreign genetic material. 5 Figure 5A
SG10201809901SA 2012-04-24 2013-04-24 Generating Pluripotent Cells De Novo SG10201809901SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261637631P 2012-04-24 2012-04-24
US201361779533P 2013-03-13 2013-03-13

Publications (1)

Publication Number Publication Date
SG10201809901SA true SG10201809901SA (en) 2018-12-28

Family

ID=49483852

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201809901SA SG10201809901SA (en) 2012-04-24 2013-04-24 Generating Pluripotent Cells De Novo
SG11201407768QA SG11201407768QA (en) 2012-04-24 2013-04-24 Generating pluripotent cells de novo

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201407768QA SG11201407768QA (en) 2012-04-24 2013-04-24 Generating pluripotent cells de novo

Country Status (11)

Country Link
US (1) US11963977B2 (en)
EP (2) EP3483261B1 (en)
JP (4) JP2015516812A (en)
KR (2) KR20200084916A (en)
CN (2) CN104718283A (en)
AU (2) AU2013251649B2 (en)
CA (1) CA2885576A1 (en)
ES (1) ES2972525T3 (en)
RU (1) RU2696071C2 (en)
SG (2) SG10201809901SA (en)
WO (1) WO2013163296A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2624139C2 (en) 2011-12-05 2017-06-30 Фэктор Байосайенс Инк. Methods and formulations for cells transfection
CA3150985A1 (en) 2012-11-01 2014-05-08 Factor Bioscience Inc. Methods and products for expressing proteins in cells
CN108165603A (en) 2013-01-25 2018-06-15 艾克斯赛尔生物科学公司 For the method for selective enrichment target cell, composition, kit and system
EP2955223B1 (en) 2013-02-08 2019-12-18 Kyoto University Production methods for megakaryocytes and platelets
US11241460B2 (en) 2013-03-15 2022-02-08 Astellas Institute For Regenerative Medicine Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
US9624471B2 (en) 2013-06-12 2017-04-18 University Of Washington Through Its Center For Commercialization Methods for maturing cardiomyocytes and uses thereof
FI3690056T3 (en) 2014-01-31 2023-03-19 Factor Bioscience Inc Methods and products for nucleic acid production and delivery
BR112016021395A8 (en) * 2014-03-19 2021-07-13 Vcell Therapeutics Inc methods of generating a pluripotent cell and preparing a test cell or tissue, using a pluripotent cell, and composition
CN107438668B (en) * 2014-12-04 2021-07-27 金旼贞 Energy-utilizing pluripotent cell inducing device and method
WO2016089178A1 (en) * 2014-12-04 2016-06-09 가톨릭관동대학교산학협력단 Device and method for inducing pluripotent cells using energy
EP3256585A4 (en) 2015-02-13 2018-08-15 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
KR101855967B1 (en) 2016-03-11 2018-05-10 가톨릭관동대학교산학협력단 Physical stimulation-mediated permeation of Environmental transition guided cellular reprogramming
KR102050852B1 (en) * 2016-03-11 2019-12-03 주식회사 스템온 Device for cell reprogramming
WO2017155166A1 (en) * 2016-03-11 2017-09-14 가톨릭관동대학교기술지주 주식회사 Cell reprogramming method using imposition of physical stimulation-mediated environmental transition
WO2017155167A1 (en) * 2016-03-11 2017-09-14 가톨릭관동대학교산학협력단 Cell reprogramming apparatus
US10456423B2 (en) 2016-06-13 2019-10-29 SMART SURGICAL, Inc. Compositions for biological systems and methods for preparing and using the same
US10426796B2 (en) 2016-06-13 2019-10-01 SMART SURGICAL, Inc. Compositions for biological systems and methods for preparing and using the same
CN116115629A (en) 2016-08-17 2023-05-16 菲克特生物科学股份有限公司 Nucleic acid products and methods of administration thereof
US20180127738A1 (en) * 2016-11-07 2018-05-10 BiomediStem, LLC Production and therapeutic uses of epinul pluripotent cells and differentiated cells derived therefrom
US20200131473A1 (en) * 2017-03-20 2020-04-30 Ifom Fondazione Istituto Firc Di Oncologia Molecolare Method of generating 2 cell-like stem cells
AU2018281936A1 (en) * 2017-06-10 2020-01-30 SMART SURGICAL, Inc. Compositions for biological systems and methods for preparing and using the same
CN107729932B (en) * 2017-10-10 2019-07-26 杭州智微信息科技有限公司 Bone marrow cell labeling method and system
KR102416171B1 (en) 2018-10-02 2022-07-06 주식회사 스템온 Reprosomes, the exosomes capable of inducing reprogramming of cells and the preparation method thereof
US10501404B1 (en) 2019-07-30 2019-12-10 Factor Bioscience Inc. Cationic lipids and transfection methods
US20210254007A1 (en) * 2020-02-14 2021-08-19 Hackensack Meridian Health, Inc. Platelet-derived mitochondria treatment and method of generating multipotent cells

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4963489A (en) 1987-04-14 1990-10-16 Marrow-Tech, Inc. Three-dimensional cell and tissue culture system
FR2687404B1 (en) 1992-02-19 1994-05-20 Centre Nal Recherc Scientifique IMMUNOLOGICALLY RELATED PEPTIDES TO PROTEINS OF A VIRAL AGENT AND THEIR BIOLOGICAL APPLICATIONS.
AU4543193A (en) 1992-06-22 1994-01-24 Henry E. Young Scar inhibitory factor and use thereof
US5672346A (en) 1992-07-27 1997-09-30 Indiana University Foundation Human stem cell compositions and methods
AU689758B2 (en) 1992-10-09 1998-04-09 Advanced Tissue Sciences, Inc. Liver reserve cells
US5753431A (en) * 1993-10-13 1998-05-19 Northeastern Ohio University Cholesterol 7 α-hydroxdylase gene regulatory elements and transcription factors
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
GB9502022D0 (en) 1995-02-02 1995-03-22 Abuljadayel Ilham M S A method for preparing lymphohaematopoietic progenitor cells
WO2002057428A1 (en) 2000-10-30 2002-07-25 University Of Massachusetts Isolation of spore-like cells from tissues exposed to extreme conditions
GB0113118D0 (en) * 2001-05-31 2001-07-18 Intercytex Ltd Stem Cells
US7575321B2 (en) 2003-10-30 2009-08-18 Welch Allyn, Inc. Apparatus and method of diagnosis of optically identifiable ophthalmic conditions
ES2579804T3 (en) * 2003-12-02 2016-08-16 Celavie Biosciences, Llc Compositions and methods for the propagation of neural progenitor cells
WO2006028723A1 (en) * 2004-09-03 2006-03-16 Moraga Biotechnology Inc. Non-embryonic totipotent blastomer-like stem cells and methods therefor
US20060084167A1 (en) 2004-10-16 2006-04-20 Cohenford Menashi A Formation of Hybrid Cells by Fusion of Lineage Committed Cells with Stem Cells
WO2006113534A1 (en) * 2005-04-15 2006-10-26 The Johns Hopkins University Immortilization of cells including neuronal cells
FR2885368A1 (en) * 2005-05-04 2006-11-10 Fred Zacouto Treating cells genetically/epigenetically to treat diseases, involves contacting nucleus of to-be-treated cell with genetic reprogramming medium having natural cytoplasm of genetic reprogramming cell, to modify biological age
US20080242594A1 (en) * 2005-09-08 2008-10-02 Mckay Ronald D G Methods for Promoting Stem Cell Proliferation and Survival
US20070087437A1 (en) 2005-10-14 2007-04-19 Jifan Hu Methods for rejuvenating cells in vitro and in vivo
US8278104B2 (en) * 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
US20070190646A1 (en) * 2006-02-10 2007-08-16 The Trustees Of The University Of Pennsylvania Regulating stem cell differentiation by controlling matrix elasticity
US20090252711A1 (en) * 2006-05-11 2009-10-08 Andrew Craig Boquest Stem Cells And Methods Of Making And Using Stem Cells
US20100135970A1 (en) * 2006-10-27 2010-06-03 Caritas St. Elizabeth Medical Center Of Boston, In Methods for Reprogramming Adult Somatic Cells and Uses Thereof
AU2008236629B2 (en) * 2007-04-07 2014-03-06 Whitehead Institute For Biomedical Research Reprogramming of somatic cells
CA2704220A1 (en) * 2007-10-30 2009-05-07 Le Centre Nationale De La Recherche Scientifique Method for conducting an assay for neutralizing antibodies
EP2096169B1 (en) 2007-10-31 2020-11-18 Kyoto University Nuclear reprogramming method
US20090280518A1 (en) * 2008-05-12 2009-11-12 Massachusetts Institute Of Technology System for high throughput measurement of mechanical properties of cells
US9550975B2 (en) 2009-07-15 2017-01-24 Mari Dezawa SSEA-3 pluripotent stem cell isolated from body tissue
EP2492715B1 (en) * 2009-10-06 2019-01-09 Canon Kabushiki Kaisha Rear attachment lens, imaging optical system, and image pickup apparatus
EP2554659A4 (en) * 2010-04-02 2013-09-25 Riken Method for preparing es cells
KR20120002134A (en) 2010-06-30 2012-01-05 서울대학교산학협력단 Method for dedifferentiations of adipose tissue stromal cells
BR112013000605B1 (en) 2010-07-09 2021-11-09 The Gid Group, Inc. USABLE APPARATUS FOR THE COLLECTION OF HUMAN BIOLOGICAL MATERIAL AND POST-COLLECTION PROCESSING OF THE COLLECTED MATERIAL, ASSEMBLY AND METHOD FOR PROCESSING HUMAN BIOLOGICAL MATERIAL

Also Published As

Publication number Publication date
EP2844738A4 (en) 2015-12-23
AU2019203943B2 (en) 2021-10-07
WO2013163296A1 (en) 2013-10-31
JP2020182480A (en) 2020-11-12
US11963977B2 (en) 2024-04-23
AU2013251649B2 (en) 2019-04-04
AU2013251649A1 (en) 2014-11-06
JP2023002805A (en) 2023-01-10
KR20150045935A (en) 2015-04-29
CN104718283A (en) 2015-06-17
EP3483261B1 (en) 2023-11-29
AU2019203943A1 (en) 2019-06-27
JP2018183145A (en) 2018-11-22
EP2844738A1 (en) 2015-03-11
US20150110749A1 (en) 2015-04-23
SG11201407768QA (en) 2015-01-29
CA2885576A1 (en) 2013-10-31
JP2015516812A (en) 2015-06-18
RU2014147093A (en) 2016-06-10
CN112048466A (en) 2020-12-08
EP3483261A1 (en) 2019-05-15
RU2696071C2 (en) 2019-07-30
KR20200084916A (en) 2020-07-13
ES2972525T3 (en) 2024-06-13

Similar Documents

Publication Publication Date Title
SG10201809901SA (en) Generating Pluripotent Cells De Novo
EP2633036A4 (en) Differentiation methods for production of glial cell populations
WO2012087965A3 (en) Cell culture platform for single cell sorting and enhanced reprogramming of ipscs
MX2010000348A (en) Single pluripotent stem cell culture.
WO2015073683A3 (en) Nuclease-mediated regulation of gene expression
MY183741A (en) Methods and compositions for increasing efficiency of targeted gene modification using oligonucleotide-mediated gene repair
MY159971A (en) Multipotent/pluripotent cells and methods
MX2015005797A (en) Production of recombinant vaccine in e. coli by enzymatic conjugation.
WO2010111422A3 (en) Induced pluripotent stem cell generation using two factors and p53 inactivation
WO2011130624A3 (en) Sustained polypeptide expression from synthetic, modified rnas and uses thereof
WO2012056109A3 (en) Plant derived cell culture material
SG10201901417UA (en) Production of proteins in glutamine-free cell culture media
GB2449772A (en) Large scale production of stem cells
EP3539380A3 (en) Improved cell composition and methods of making the same
RS54073B1 (en) Stromal stem cells
EP2588594A4 (en) Methods for culturing undifferentiated cells using sustained release compositions
SG10201810830UA (en) Cell culture compositions and methods for polypeptide production
MX2018014043A (en) Cell culture compositions with antioxidants and methods for polypeptide production.
WO2016061071A8 (en) Generation of keratinocytes from pluripotent stem cells and maintenance of keratinocyte cultures
MX2012002019A (en) Deepwell plate system with lid.
EP2582792A4 (en) Cardiomyocyte medium with dialyzed serum
EA201170024A1 (en) METHODS OF GETTING HIGH DENSITY OF VIABLE CELLS IN THE CULTURE OF MAMMALIAN CELLS
MX2015011781A (en) Cell culture media and methods of antibody production.
WO2011100286A3 (en) Compositions and methods of generating a differentiated mesodermal cell
WO2015073625A3 (en) Synergistic genome-nonintegrating reprogramming by micrornas and transcription factors